Fagron N.V.
ARSUF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.89B
Close$
$38.11
47.7% upside
Current Fair Value
47.7% upsideUndervalued by 47.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.89 Billion |
|---|---|
| Enterprise Value | $2.40 Billion |
| Annual dividend | $0.46 |
| Dividend yield | 1.69% |
| Earnings per Share | $1.24 |
| Beta | 0.39 |
| Outstanding Shares | 73,295,000 |
Return
| Return on Equity | 29.84% |
|---|---|
| Return on Assets | 11.63% |
| Return on Invested Capital | 23.27% |
Valuation & Multiples
| P/E Ratio | 18.92 |
|---|---|
| PEG | 1202.2 |
| Price to Sales | 0.99 |
| Price to Book Ratio | 3.23 |
| Enterprise Value to Revenue | 1.23 |
| Enterprise Value to EBIT | 8.28 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 1.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$619.57 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Fagron N.V.
4,134 employees
CEO: Rafael Padilla
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond ...